Drug Trial Radar · NCT07542158
Ultralow Dose PET Imaging of 18F-FDOPA
Last checked: Nov 19, 2026Latest source record: Apr 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Enrolling by invitation
Enrollment
200
Planned (sponsor's estimate)
Start
May 12, 2025
Primary completion
Jun 30, 2030
Study completion Jun 30, 2030
Sponsor
- Lead sponsor
- Akiva MintzAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Apr 21, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Diagnostic
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 120 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to evaluate an investigational ultralow dose PET imaging technique for Parkinsonian syndromes, neuroendocrine tumors, and gliomas detection and monitoring. The main question it aims to answer is: Can the investigators optimize the timing, scan duration, and image reconstruction to reduce the radiation dose 10-100 fold of the current clinical standard? Participants will be injected with a radioactive tracer called 18F-FDOPA and be imaged on a new type of high sensitivity PET scanner for up to 3 hours.
Conditions
- Heathy Volunteer
- Parkinsonian Syndromes
- Neuroendocrine (NE) Tumors
- Gliomas
Interventions
18F-FDOPADrug
Participants will be injected with 18F-FDOPA and imaged for up to 3 hours on a PET scanner
Primary outcomes
What the sponsor says the trial is designed to measure.
- Signal-to-Noise Ratio (SNR)Time frame: Single timepoint (Day 1, imaging visit); aggregated analysis conducted annually using data from the prior 12 months, through study completion (up to 5 years).
- Contrast-to-Noise Ratio (CNR)Time frame: Single timepoint (Day 1, imaging visit); aggregated analysis conducted annually using data from the prior 12 months, through study completion (up to 5 years).
- Coefficient of Variation (COV)Time frame: Single timepoint (Day 1, imaging visit); aggregated analysis conducted annually using data from the prior 12 months, through study completion (up to 5 years).
- Spatial Resolution (Full Width at Half Maximum - FWHM)Time frame: Single timepoint (Day 1, imaging visit); aggregated analysis conducted annually using data from the prior 12 months, through study completion (up to 5 years).
- Target-to-Background Ratio (TBR)Time frame: Single timepoint (Day 1, imaging visit); aggregated analysis conducted annually using data from the prior 12 months, through study completion (up to 5 years).
- Qualitative Image Quality Score (Likert Scale)Time frame: Single timepoint (Day 1, imaging visit); aggregated analysis conducted annually using data from the prior 12 months, through study completion (up to 5 years).
- Inter-reader Agreement (Weighted Kappa Statistics)Time frame: Single timepoint (Day 1, imaging visit); aggregated analysis conducted annually using data from the prior 12 months, through study completion (up to 5 years).
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Nuclear Imaging Institute
Englewood, New Jersey
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.